loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Ripasudil

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Ripasudil

    ACTIVE PHARMA INGREDIENTS

    PRICE INFORMATION

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 78,988Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aerie Announces Positive Phase 3 Topline Results for Netarsudil in Japan
    Aerie Announces Positive Phase 3 Topline Results for Netarsudil in Japan

    12 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211012005106/en

    BUSINESSWIRE
    12 Oct 2021
    Share Share
    Aerie Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil
    Aerie Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil

    17 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210617005036/en

    BUSINESSWIRE
    17 Jun 2021
    Share Share
    Rho kinase inhibitor,
    Rho kinase inhibitor, "Ripasudil Hydrochloride Hydrate" INDapp for Ph2 clinical

    03 Sep 2019

    // PR NEWSWIR

    https://www.prnewswire.com/news-releases/rho-kinase-inhibitor-ripasudil-hydrochloride-hydrate-ind-application-for-phase-2-clinical-study-in-the-united-states-indication-for-corneal-endothelial-diseases-developmental-code-k-321-300909856.html

    PR NEWSWIR
    03 Sep 2019
    Share Share